Hoth Therapeutics partners with Wise Systems International to leverage AI technology, specifically Nvidia’s BioNeMo platform, aiming to accelerate drug discovery processes and deliver novel therapeutics. This collaboration reflects a growing trend of tech-biopharma partnerships in the industry.
Hoth Therapeutics and Wise Systems International to Collaborate on AI-driven Drug Discovery
New York, June 10, 2024 — Hoth Therapeutics, Inc., a biopharmaceutical organisation listed on NASDAQ, announced a joint development agreement with Wise Systems International SRL. The collaboration aims to enhance drug discovery processes through the utilisation of artificial intelligence, specifically leveraging Nvidia’s BioNeMo AI platform.
The BioNeMo generative AI platform is designed to aid researchers and developers in creating and integrating advanced AI applications across the spectrum of drug discovery activities. This includes stages such as target identification and lead optimisation, made possible through AI-based workflows. According to the agreement, Wise Systems International (SRL) will assist Hoth Therapeutics in employing this AI technology to expand and refine its therapeutic pipeline.
Robert Antofe from Wise Systems International highlighted the potential benefits of the partnership, expressing enthusiasm about the opportunity to apply their AI expertise to contribute to both companies’ growth in the pharmaceutical sector.
Robb Knie, Chief Executive Officer of Hoth Therapeutics, remarked on the potential of Nvidia’s BioNeMo platform. “We believe it is best in class,” Knie stated. “With SRL’s assistance, we anticipate significant advancements in our intellectual property and pipeline, ultimately striving to deliver novel therapeutics to patients.”
This collaboration is seen as a strategic move for Hoth Therapeutics, a company known for its patient-focused approach in the biopharmaceutical industry. The company specialises in early-stage pharmaceutical research, pushing drugs from the discovery phase through to pre-clinical and clinical testing. By integrating cutting-edge AI technologies, Hoth Therapeutics aims to accelerate the drug discovery process, potentially leading to more efficient development of treatments that could improve patient outcomes.
Wise Systems International SRL, on the other hand, brings its AI expertise to the table, complementing Hoth Therapeutics’ pharmaceutical focus. This partnership aligns with broader trends in the industry where AI is increasingly being used to streamline and enhance drug discovery processes. The use of AI technologies, such as Nvidia’s BioNeMo, is seen as a promising tool in handling the complexities and vast data sets involved in pharmaceutical research.
Hoth Therapeutics’ announcement follows a growing trend of collaborations between technology firms and biopharmaceutical companies, aiming to harness the power of AI to revolutionise healthcare and drug development. With the increasing capabilities of AI, such collaborations are expected to bring about more rapid and cost-effective advancements in medical research.
For further information on Hoth Therapeutics, their research initiatives, and ongoing projects, interested parties can visit their official website.
Contacts:
– Investor Relations: LR Advisors LLC, [email: inv[email protected]], [website: www.hoththerapeutics.com], [phone: (678) 570-6791]
This article is based on an announcement made by Hoth Therapeutics, Inc. and aims to present an objective overview of the strategic collaboration between Hoth Therapeutics and Wise Systems International SRL, placing it within the broader context of trends in biopharmaceutical research and artificial intelligence.
